ArticleJournal of thoracic disease2025
Epidemiological features and risk factors of SARS-CoV-2 reinfection: a retrospective cohort analysis in Xiamen, China.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comorbidities increase the severity of COVID-19: an analysis and epidemiological study conducted in Algeria.The Libyan journal of medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Recently, surges in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reinfections in China have raised public concern. We investigated the epidemiological features and risk factors for SARS-CoV-2 reinfection in China. Methods: A retrospective cohort study was conducted in Xiamen, China (2021-2023) with two subcohorts: Delta-Omicron (cohort 1) and Omicron-Omicron (cohort 2). Descriptive analysis and ensemble modeling were employed to evaluate reinfections. Results: A total of 327 cases without fatalities were included. Reinfections accounted for 14.68% of cases, with 22.51% in cohort 1 and 3.68% in cohort 2. Compared with primary infections (PIs) (99.69% symptomatic, 56.54% hospitalized), reinfections were less severe, with fewer symptomatic instances (47.92%) and hospitalizations (4.65%). The majority of reinfections (83.33%) occurred following the relaxation of strict public health and social measures. The median time interval between PI and reinfection was longer for cohort 1 (462 days) than for cohort 2 (280 days). Reinfection risks were noted among lesser developed regions, those without persistent PI, those with primary Delta variant infection, government and hospital workers, and unvaccinated individuals. Conclusions: SARS-CoV-2 reinfections are generally less severe and are influenced by the relaxation of control measures, viral evolution, and changing patterns of population immunity and contact; this underscores the need for ongoing surveillance and targeted public health strategies to manage future infection waves.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.